ESTRO 2024 - Abstract Book

S157

Brachytherapy - Breast

ESTRO 2024

outcome. After surgery 53.7% (n=73) was excellent, 41.2% (n=56) good and 5.1% (n=7) fair. Only 3.7% (n=5) of patients changed the initial cosmetic from excellent to good after brachytherapy. The final cosmetic outcome was good/excellent in 94.9% (n=129) and fair in 5.1% (n=7). To date, no relapse has occurred.

Conclusion:

Three-fraction HDR brachytherapy was well-tolerated. Although acute and late toxicities or adverse cosmetic outcomes were seen, very few were grade 2 or higher and compare favourably to those reported in prior 8-10 fraction APBI studies. This study provides early single institutional evidence that three-fraction APBI may become a feasible treatment alternative.

Keywords: Three-fraction APBI, Toxicity, Cosmesis

References:

1. Guinot JL, Gonzalez-Perez V, Meszaros N, Major T, Najjari-Jamal D, Gutierrez-Miguelez C, Santos MA, Smanyko V, Laplana M, Polgar C; GEC-ESTRO Breast Working Group2. Very accelerated partial breast irradiation Phase I-II multicenter trial (VAPBI): Feasibility and early results. Brachytherapy. 2021 Mar-Apr;20(2):332-338. doi: 10.1016/j.brachy.2020.10.010. Epub 2020 Nov 19. PMID: 33223449. 2. Chung EM, Nguyen AT, Mirhadi A, Steers JM, Phillips T, Atkins KM, Burnison M, Shiao SL, Kamrava M. A Single Institution Retrospective Study of Three-Fraction HDR Accelerated Partial Breast Irradiation. Brachytherapy. 2023 May-Jun;22(3):361-367. doi: 10.1016/j.brachy.2023.02.006. Epub 2023 Mar 28. PMID: 36997449. 3. Charfare H, MacLatchie E, Cordier C , Bradley M, Eadie C, Byrtus A, Burnet K, Chapman D, Wishart GC and Purushotham AD : A comparison of different methods of assessing cosmetic outcome following breast-conserving surgery and factors influencing cosmetic outcome. BJMP 2010;3(1):310 ISSN 1757-8515 4.Shaitelman SF, Amendola B, Khan A, Beriwal S, Rabinovitch R, Demanes DJ, Kim LH, Cuttino L. American Brachytherapy Society Task Group Report: Long-term control and toxicity with brachytherapy for localized breast cancer. Brachytherapy. 2017 Jan-Feb;16(1):13-21. doi: 10.1016/j.brachy.2016.04.392. Epub 2016 Jun 7. PMID: 27288156. 5.Simon LE, Scanderbeg D, Einck J, Mayadev J, Brown D, Wallace A, Blair S, Yashar C, Huynh-Le MP. Retrospective review of three-fractioned accelerated partial breast irradiation. Brachytherapy. 2022 Jul-Aug;21(4):487-493. doi: 10.1016/j.brachy.2022.02.002. Epub 2022 Apr 13. PMID: 35428569. 6.Khan AJ, Chen PY, Yashar C, Poppe MM, Li L, Abou Yehia Z, Vicini FA, Moore D, Dale R, Arthur D, Shah C, Haffty BG, Kuske R. Three-Fraction Accelerated Partial Breast Irradiation (APBI) Delivered With Brachytherapy Applicators Is Feasible and Safe: First Results From the TRIUMPH-T Trial. Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):67-74. doi: 10.1016/j.ijrobp.2018.12.050. Epub 2019 Jan 4. PMID: 30611839; PMCID: PMC7373303.

2246

Proffered Paper

Five-year results of Very Accelerated Partial Breast Irradiation VAPBI phase I-II GEC-ESTRO trial